This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Quantification of Human Adipogenesis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Matthew Steinhauser, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01257997
First received: December 9, 2010
Last updated: August 25, 2016
Last verified: August 2016
  Purpose
This pilot study is using a novel technology to measure the rate of turnover of new fat cells. Analysis of volunteer samples is ongoing, however the study is currently not enrolling new volunteers.

Condition Intervention
Healthy Biological: 15N-Thymidine, 2H-Water

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Quantification of Human Adipogenesis

Further study details as provided by Matthew Steinhauser, MD, Brigham and Women's Hospital:

Primary Outcome Measures:
  • Quantifying human adipogenesis-counting the number of new fat cells. [ Time Frame: 4 weeks-7 months ]

Biospecimen Retention:   Samples Without DNA
Fat biopsy. Oral mucosal smear. White blood cells.

Estimated Enrollment: 20
Study Start Date: December 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Healthy subjects
18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
Biological: 15N-Thymidine, 2H-Water

Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).

Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).


  Eligibility

Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers. Aged 18-49 years. Free of significant chronic medical illness. Free of illicit substance abuse.
Criteria

Inclusion Criteria:

  • Aged 18-49 years.
  • Healthy.

Exclusion Criteria:

  • Significant chronic medical illness.
  • Illicit substance or alcohol abuse.
  • Body mass index > 27 kg/meters squared.
  • Underweight (BMI < 20 kg/m2).
  • History of keloid formation (excessive scarring).
  • Pregnant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01257997

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Matthew L Steinhauser, MD Brigham and Women's Hospital
  More Information

Publications:
Responsible Party: Matthew Steinhauser, MD, Attending Physician, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01257997     History of Changes
Other Study ID Numbers: BWH-2010p001900
Study First Received: December 9, 2010
Last Updated: August 25, 2016

Keywords provided by Matthew Steinhauser, MD, Brigham and Women's Hospital:
No specific experimental conditions

ClinicalTrials.gov processed this record on September 20, 2017